• If you are wondering whether Oncolytics Biotech's current share price reflects its true worth, you are not alone, many investors are asking the same question before making their next move.
• The stock recently closed at US$1.06, with returns of 3.9% over 7 days, 19.7% over 30 days, 7.8% year to date and 65.1% over 1 year, while the 3 year and 5 year returns sit at 14.5% and 65.7% declines respectively.
• These mixed returns have kept Oncolytics Biotech on the radar for investors who follow biotech names for shifts in risk appetite and potential catalysts. Recent news coverage has focused more on the company's long term prospects and funding runway than on short term trading activity, giving important context to the share price moves.
• On our checks, Oncolytics Biotech scores a 2 out of 6 valuation score. This suggests the upcoming sections will need to unpack different valuation approaches and then finish with a more rounded way to think about what the current price really means for you.

Oncolytics Biotech scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Oncolytics Biotech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a single present value.

For Oncolytics Biotech, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in CA$. The latest twelve month free cash flow stands at a loss of CA$26.48 million. Analyst and extrapolated projections show free cash flow staying negative in the medium term, then moving to an estimated CA$169.40 million by 2030, with further increases in the following years according to the supplied projections.

Bringing all those projected cash flows back to today, the DCF output suggests an estimated intrinsic value of about CA$88.09 per share. Compared with the recent share price of US$1.06, this implies the stock screens as 98.8% undervalued under this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Oncolytics Biotech is undervalued by 98.8%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Oncolytics Biotech Price vs Book

For companies that are not yet profitable, earnings based metrics like the P/E ratio are less useful, so investors often look at asset based measures such as Price to Book, or P/B, instead. P/B compares the market value of the equity with the accounting value of net assets, which can be a practical anchor for early stage or loss making businesses.

In general, higher growth potential and lower perceived risk can justify a higher P/B multiple. Slower growth or higher risk usually point to a lower, more conservative multiple. For Oncolytics Biotech, the current P/B ratio is 1,347.18x. That sits far above the Biotechs industry average of 2.70x and the peer group average of 3.98x.

Simply Wall St also calculates a proprietary Fair Ratio for P/B, which is the multiple it would expect based on factors such as earnings growth, profit margins, industry, market cap and specific risk profile. This tends to be more tailored than a simple comparison with industry or peers because it adjusts for the company’s own characteristics instead of assuming all biotechs should trade on the same multiple. As the Fair Ratio for Oncolytics Biotech is not available here, it is not possible to say whether the current P/B looks overvalued, undervalued, or about right relative to that benchmark.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Oncolytics Biotech Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your story about a company linked directly to the numbers you care about, such as fair value, and your expectations for future revenue, earnings and margins.

A Narrative connects three pieces: what you think is happening with the business, how that feeds into a financial forecast, and the fair value that falls out of those assumptions.

On Simply Wall St, millions of investors share and explore these Narratives on the Community page, where you can see how others think about a stock and easily build your own without needing complex models.

Each Narrative helps you decide what action makes sense for you by comparing its Fair Value with the current Price. It also automatically refreshes when new information such as news or earnings is added to the platform.

For example, one Oncolytics Biotech Narrative might assume very conservative future revenue and margin outcomes and arrive at a Fair Value well below the current price. Another Narrative might assume stronger progress on key programs and produce a Fair Value well above where the shares trade today.

Do you think there's more to the story for Oncolytics Biotech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.